Neurolixis to present results of successful NLX-112 proof-of-concept clinical trial at the World Parkinson’s Congress – World News Report – Medical Marijuana Program Connection
Neurolixis to present NLX-112 results at Barcelona WPC meeting A First-in-Class Highly Selective and Efficacious Serotonin 5-HT1A Receptor Agonist for treatment of Parkinson’s Disease The WPC is a…
Read more Neurolixis to present results of successful NLX-112 proof-of-concept clinical trial at the World Parkinson’s Congress – World News Report – Medical Marijuana Program Connection